Avanos Medical - AVNS Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings or view top-rated stocks.

2 brokers have issued 12 month target prices for Avanos Medical's stock. Their AVNS share price forecasts range from $28.00 to $34.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 5.1% from the stock's current price.
View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts.

Avanos Medical's stock was trading at $27.06 at the beginning of the year. Since then, AVNS stock has increased by 5.5% and is now trading at $28.54.
View the best growth stocks for 2023 here.

Avanos Medical saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 1,010,000 shares, an increase of 10.9% from the January 31st total of 910,700 shares. Based on an average daily trading volume, of 210,300 shares, the days-to-cover ratio is presently 4.8 days. Approximately 2.2% of the company's stock are sold short.
View Avanos Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AVNS earnings forecast.

Avanos Medical, Inc. (NYSE:AVNS) posted its quarterly earnings data on Tuesday, February, 21st. The company reported $0.60 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.12. The firm had revenue of $217.50 million for the quarter, compared to the consensus estimate of $217.30 million. Avanos Medical had a net margin of 6.07% and a trailing twelve-month return on equity of 6.13%. Avanos Medical's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.46 EPS.

ETFs with the largest weight of Avanos Medical (NYSE:AVNS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Active Factor Small Cap ETF (AFSM), Pacer US Small Cap Cash Cows 100 ETF (CALF), Royce Quant Small-Cap Quality Value ETF (SQLV), First Trust Small Cap Value AlphaDEX Fund (FYT) and SPDR S&P 600 Small CapValue ETF (SLYV).

Avanos Medical issued an update on its FY 2023 earnings guidance on Tuesday, February, 21st. The company provided earnings per share (EPS) guidance of $1.60-$1.80 for the period, compared to the consensus earnings per share estimate of $1.68. The company issued revenue guidance of -.

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (6.22%), RGM Capital LLC (5.71%), Macquarie Group Ltd. (3.52%), Neuberger Berman Group LLC (1.88%), Geode Capital Management LLC (1.82%) and Charles Schwab Investment Management Inc. (1.44%). Insiders that own company stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends.

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVNS stock can currently be purchased for approximately $28.54.

Avanos Medical (NYSE:AVNS) has a market capitalization of $1.33 billion and generates $820 million in revenue each year. The company earns $50.50 million in net income (profit) each year or $1.05 on an earnings per share basis.

The company employs 4,044 workers across the globe.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.